ALDH1A1 and non-small cell lung carcinoma: Targeting these highly expressed metabolic enzymes may be a suitable strategy to overcome cisplatin resistance, as has previously been demonstrated for Aldh1a1 in non-small-cell lung cancer (NSCLC) (MacDonagh et al., 2017).